Literature DB >> 23423643

Interstrain differences in chronic hepatitis and tumor development in a murine model of inflammation-mediated hepatocarcinogenesis.

Tamara Potikha1, Evgeniy Stoyanov, Orit Pappo, Antonina Frolov, Lina Mizrahi, Deborah Olam, Temima Shnitzer-Perlman, Ido Weiss, Neta Barashi, Amnon Peled, Gabriele Sass, Gisa Tiegs, Francoise Poirier, Gabriel A Rabinovich, Eithan Galun, Daniel Goldenberg.   

Abstract

UNLABELLED: Chronic inflammation is strongly associated with an increased risk for hepatocellular carcinoma (HCC) development. The multidrug resistance 2 (Mdr2)-knockout (KO) mouse (adenosine triphosphate-binding cassette b4(-/-) ), a model of inflammation-mediated HCC, develops chronic cholestatic hepatitis at an early age and HCC at an adult age. To delineate factors contributing to hepatocarcinogenesis, we compared the severity of early chronic hepatitis and late HCC development in two Mdr2-KO strains: Friend virus B-type/N (FVB) and C57 black 6 (B6). We demonstrated that hepatocarcinogenesis was significantly less efficient in the Mdr2-KO/B6 mice versus the Mdr2-KO/FVB mice; this difference was more prominent in males. Chronic hepatitis in the Mdr2-KO/B6 males was more severe at 1 month of age but was less severe at 3 months of age in comparison with age-matched Mdr2-KO/FVB males. A comparative genome-scale gene expression analysis of male livers of both strains at 3 months of age revealed both common and strain-specific aberrantly expressed genes, including genes associated with the regulation of inflammation, the response to oxidative stress, and lipid metabolism. One of these regulators, galectin-1 (Gal-1), possesses both anti-inflammatory and protumorigenic activities. To study its regulatory role in the liver, we transferred the Gal-1-KO mutation (lectin galactoside-binding soluble 1(-/-) ) from the B6 strain to the FVB strain, and we demonstrated that endogenous Gal-1 protected the liver against concanavalin A-induced hepatitis with the B6 genetic background but not the FVB genetic background.
CONCLUSION: Decreased chronic hepatitis in Mdr2-KO/B6 mice at the age of 3 months correlated with a significant retardation of liver tumor development in this strain versus the Mdr2-KO/FVB strain. We found candidate factors that may determine strain-specific differences in the course of chronic hepatitis and HCC development in the Mdr2-KO model, including inefficient anti-inflammatory activity of the endogenous lectin Gal-1 in the FVB strain.
Copyright © 2013 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23423643     DOI: 10.1002/hep.26335

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  20 in total

1.  Detection of promoter methylation status of suppressor of cytokine signaling 3 (SOCS3) in tissue and plasma from Chinese patients with different hepatic diseases.

Authors:  Ling Wei; Yuan Huang; Rongce Zhao; Jing Zhang; Qiuying Liu; Weibo Liang; Xueqin Ding; Bo Gao; Bo Li; Chengjun Sun; Jingyang He; Xiaoqin Yu; Zhongjian Liu; Aimin Sun; Yang Qin
Journal:  Clin Exp Med       Date:  2017-09-26       Impact factor: 3.984

2.  Stress of Strains: Inbred Mice in Liver Research.

Authors:  Arlin B Rogers
Journal:  Gene Expr       Date:  2018-08-09

3.  Cholestatic liver disease results increased production of reactive aldehydes and an atypical periportal hepatic antioxidant response.

Authors:  Colin T Shearn; Blair Fennimore; David J Orlicky; Yue R Gao; Laura M Saba; Kayla D Battista; Stefanos Aivazidis; Mohammed Assiri; Peter S Harris; Cole Michel; Gary F Merrill; Edward E Schmidt; Sean P Colgan; Dennis R Petersen
Journal:  Free Radic Biol Med       Date:  2019-08-01       Impact factor: 7.376

4.  The pro-oncogenic effect of the lncRNA H19 in the development of chronic inflammation-mediated hepatocellular carcinoma.

Authors:  Lika Gamaev; Lina Mizrahi; Tomer Friehmann; Nofar Rosenberg; Orit Pappo; Devorah Olam; Evelyne Zeira; Keren Bahar Halpern; Stefano Caruso; Jessica Zucman-Rossi; Jonathan H Axelrod; Eithan Galun; Daniel S Goldenberg
Journal:  Oncogene       Date:  2020-10-22       Impact factor: 9.867

Review 5.  Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma.

Authors:  María L Bacigalupo; Malena Manzi; Gabriel A Rabinovich; María F Troncoso
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

6.  Lack of galectin-1 exacerbates chronic hepatitis, liver fibrosis, and carcinogenesis in murine hepatocellular carcinoma model.

Authors:  Tamara Potikha; Orit Pappo; Lina Mizrahi; Devorah Olam; Sebastián M Maller; Gabriel A Rabinovich; Eithan Galun; Daniel S Goldenberg
Journal:  FASEB J       Date:  2019-03-21       Impact factor: 5.834

7.  Evaluation of 11C-acetate and 18F-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma.

Authors:  Paul R Territo; Mary Maluccio; Amanda A Riley; Brian P McCarthy; James Fletcher; Mark Tann; Romil Saxena; Nicholas J Skill
Journal:  BMC Med Imaging       Date:  2015-05-16       Impact factor: 1.930

8.  Chronic liver inflammation modifies DNA methylation at the precancerous stage of murine hepatocarcinogenesis.

Authors:  Evgeniy Stoyanov; Guy Ludwig; Lina Mizrahi; Devorah Olam; Temima Schnitzer-Perlman; Elena Tasika; Gabriele Sass; Gisa Tiegs; Yong Jiang; Ting Nie; James Kohler; Raymond F Schinazi; Paula M Vertino; Howard Cedar; Eithan Galun; Daniel Goldenberg
Journal:  Oncotarget       Date:  2015-05-10

9.  Specific genomic and transcriptomic aberrations in tumors induced by partial hepatectomy of a chronically inflamed murine liver.

Authors:  Ezra Ella; Denise Heim; Evgeniy Stoyanov; Rona Harari-Steinfeld; Israel Steinfeld; Orit Pappo; Temima Schnitzer Perlman; Natalie Nachmansson; Ludmila Rivkin; Devorah Olam; Rinat Abramovitch; Henning Wege; Eithan Galun; Daniel Goldenberg
Journal:  Oncotarget       Date:  2014-11-15

Review 10.  Creatine in T Cell Antitumor Immunity and Cancer Immunotherapy.

Authors:  Bo Li; Lili Yang
Journal:  Nutrients       Date:  2021-05-13       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.